Abstract 1863P
Background
A descriptive, cross-sectional, multicenter study was carried out among the nursing staff working in several departments caring for cancer patients (Carcinology Sousse, Monastir, Sfax, Institut Salah Azaiez and Ariana).
Methods
The instrument used to measure CE was the "Professional quality of life" (PRO-QOL version5), which is composed of 3 subscales: 10 items to measure compassion satisfaction (SC), 10 items to measure professional exhaustion (PE) and 10 items to measure secondary traumatic stress (STS).
Results
A total of 120 health personnel responded to the questionnaire. The average age of the participants was 36.13±8.06 with a clear female predominance (sex ratio=0.29). Most respondents were physicians (55.9%). The mean CS score was 33.57±6.24, which is consistent with an average level of CS. However, 13.3% of the staff had a high SC score. The mean PE score was 29.88±5.12, which corresponds to an average level of PE. Only 10.9% had a low PE score. The mean STS score was 33.16±7.56, which corresponds to an average level of STS. However, 17.5% had a high STS score.
Conclusions
Compassion fatigue can lead to real burnout. Its prevention, detection and implementation of solutions to stem the process is essential.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
1-Service of carcinological medicine CHU FarhatHached Sousse 2- Hospital hygiene service CHU FarhatHached Sousse 1-Service of carcinological medicine CHU FarhatHached Sousse 2- Hospital hygiene service CHU FarhatHached Sousse Service of carcinological medicine CHU FarhatHached Sousse and Hospital hygiene service CHU FarhatHached Sousse.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05